StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 7 sell-side ratings as of 2025-12-01. Stonvex does not endorse these ratings.
Next report date, year-over-year trend, and recent quarter history.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows VSEE's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
VSee Health Inc is a telehealth software platform offer a comprehensive telehealth platform for U.S. hospitals and enterprises. Through VSee Lab, the company offer a set of telehealth software building blocks, data connectors, and workflow templates that can be rapidly configured into the clients workflows. Companies offerings allow clinicians without programming experience to configure building blocks into their existing workflow without requiring programmers. These set of building blocks can connect to electronic medical record systems such as EPIC and Cerner via HL7, FHIR, and sFTP. The entire telehealth platform sits on a scalable server architecture and is HIPAA compliant and SOC2 externally audited.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $3.16M | $14.62M | $10.69M | $6.71M |
Operating Income | $-2.97M | $-9.58M | $-6.14M | $-4.09M |
Net Income | $-2.60M | $-14.71M | $-6.86M | $-6.57M |
EPS (Diluted) | $-0.05 | $-0.73 | $-0.42 | $-0.40 |
Total Assets | $19.02M | $22.41M | $18.71M | $18.21M |
Total Liabilities | $12.70M | $16.96M | $24.28M | $23.95M |
Cash & Equivalents | $1.35M | $5.27M | $472.76K | $291.60K |
Free Cash Flow OCF − CapEx | $-2.48M | $-3.48M | $-1.54M | $-780.56K |
Shares Outstanding | 47.30M | 33.19M | 17.02M | 16.42M |
No sell-side coverage available for VSEE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.